Abstract:RAS mutations are found in 30% of human cancers and are characterized by hotspot mutations at codons G12, G13, and Q61. This results in constitutively activated RAS proteins. Despite recent advances in drug design and the emergence of covalent inhibitors, effectively targeting mutant RAS remains challenging. Our group previously identified the tumor suppressor protein DIRAS3, which directly binds Ras and inhibits its function by disrupting KRAS dimers/nanoclusters and blocking effector activation. DIRAS3 expression reduced cancer cell growth in pancreatic and ovarian cancers. To determine whether DIRAS3 plays a definitive role in inhibiting mutant KRAS, we comprehensively characterized DIRAS3's RAS-inhibitory effects using RASless mouse embryo fibroblast (MEF) cells as a model system lacking endogenous RAS isoforms. We ectopically expressed various KRAS mutations in these cells and then examined DIRAS3's effect on each KRAS mutant clone. We analyzed downstream RAS signaling, colony formation, cell viability, and toxicity. Our results showed that DIRAS3 significantly inhibited RAS-dependent colony formation in KRAS mutant (G12C, G12D, G12V, G13D, G12R, Q61R, Q61L) but not wild-type KRAS clones. However, when we added epidermal growth factor (EGF) to the medium, DIRAS3 expression inhibited wild-type KRAS activity, decreasing colony formation. This suggests that DIRAS3 selectively affects the active, GTP-bound form of KRAS and downstream signaling. Additionally, DIRAS3 expression decreased Erk1/2 phosphorylation in MEF cells with mutant KRAS, but not in the cells with a BRAFV600E mutation. This indicates that DIRAS3 specifically inhibits the KRAS-mediated MEK/ERK signaling, cell proliferation, and cytotoxicity. Moreover, to determine the critical region for DIRAS3's RAS-inhibitory function, we compared wild-type DIRAS3 and deletions (ΔNTE, ΔCTE, ΔNCTE). Our results showed both termini are required to effectively suppress clonogenic growth, emphasizing the requirement for DIRAS3 to anchor to the plasma membrane and interact with the RAS dimer interface to inhibit RAS-dependent tumor growth. In conclusion, our findings underscore the potent and specific inhibitory effects of DIRAS3 on RAS-driven oncogenesis, positioning it as a promising pan-RAS inhibitor for RAS-mutant cancers. Citation Format: Gamze Bildik, Junchen Liu, Weiqun Mao, Hailing Yang, John F. Hancock, Robert C. Bast, Zhen Lu. DIRAS3 inhibits oncogenic RAS signaling and RAS-dependent cell growth driven by prevalent KRAS hot spot mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1215.

DIRAS3 Enhances RNF19B-mediated RAC1 Ubiquitination and Degradation in Non-Small-cell Lung Cancer Cells

Diverse Ras-related GTPase DIRAS2, downregulated by PSMD2 in a proteasome-mediated way, inhibits colorectal cancer proliferation by blocking NF-B signaling

ITPR1-AS1 Promotes Small Cell Lung Cancer Metastasis by Facilitating P21HRAS Splicing and Stabilizing DDX3X to Activate the Craf-Mek-erk Cascade.

circ_rac GTPase–Activating Protein 1 Facilitates Stemness and Metastasis of Non–Small Cell Lung Cancer via Polypyrimidine Tract–Binding Protein 1 Recruitment to Promote Sirtuin-3–Mediated Replication Timing Regulatory Factor 1 Deacetylation

RNAa and Vector-Mediated Overexpression of DIRAS1 Suppresses Tumor Growth and Migration in Renal Cell Carcinoma

Silencing lncRNA‐DARS‐AS1 suppresses nonsmall cell lung cancer progression by stimulating miR‐302a‐3p to inhibit ACAT1 expression

RNF216 Promotes Occurrence and Progression of Cholangiocarcinoma via Regulation of the DIAPH3 Ubiquitination

Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer.

RCCD1 Depletion Attenuates TGF-β-induced EMT and Cell Migration by Stabilizing Cytoskeletal Microtubules in NSCLC Cells.

DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas

Abstract 1215: DIRAS3 inhibits oncogenic RAS signaling and RAS-dependent cell growth driven by prevalent KRAS hot spot mutations

RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer

Identification of RAC1 in promoting brain metastasis of lung adenocarcinoma using single-cell transcriptome sequencing

DARS-AS1 Promotes Clear Cell Renal Cell Carcinoma by Sequestering Mir-194-5p to Up-Regulate DARS

Rac1 Overexpression is Correlated with Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Non-Small Cell Lung Cancer.

The SWI/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-β signaling

Oncogenic DIRAS3 Promotes Malignant Phenotypes of Glioma by Activating EGFR-AKT Signaling

STAT3/miR-135b/NF-κB Axis Confers Aggressiveness and Unfavorable Prognosis in Non-Small-cell Lung Cancer

High Expression of Rabl3 is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer Via Repression of MAPK8/9/10-Mediated Autophagy

Long Noncoding RNA MRCCAT1 Promotes Metastasis of Clear Cell Renal Cell Carcinoma Via Inhibiting NPR3 and Activating P38-Mapk Signaling

CRIF1 Promotes the Progression of Non-Small-cell Lung Cancer by SIRT3- Mediated Deacetylation of PYCR1.